TransMedics Group (NASDAQ:TMDX – Get Free Report) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Monday, Zacks reports.
A number of other research firms also recently weighed in on TMDX. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. UBS Group decreased their price target on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 5th. Needham & Company LLC reaffirmed a “buy” rating on shares of TransMedics Group in a research report on Friday, September 11th. TD Cowen reaffirmed a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a research report on Tuesday, September 8th. Finally, Canaccord Genuity Group dropped their price objective on shares of TransMedics Group from $95.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday, October 13th. Five investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $115.60.
Check Out Our Latest Report on TransMedics Group
TransMedics Group Stock Performance
Shares of TMDX stock opened at $67.34 on Monday. TransMedics Group has a 52 week low of $60.10 and a 52 week high of $156.00. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of 33.84, a PEG ratio of 0.92 and a beta of 2.14. The company has a 50-day simple moving average of $80.57 and a 200 day simple moving average of $94.17. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). The company had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm’s revenue was up 20.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.92 earnings per share. On average, sell-side analysts predict that TransMedics Group will post 1.46 earnings per share for the current year.
Insiders Place Their Bets
In other TransMedics Group news, Director David Weill bought 1,336 shares of TransMedics Group stock in a transaction on Friday, September 11th. The shares were purchased at an average cost of $81.63 per share, with a total value of $109,057.68. Following the acquisition, the director directly owned 16,392 shares of the company’s stock, valued at $1,338,078.96. The trade was a 8.87% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.90% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On TransMedics Group
Large investors have recently added to or reduced their stakes in the business. Headlands Technologies LLC acquired a new stake in TransMedics Group in the second quarter worth $1,634,000. The Manufacturers Life Insurance Company acquired a new position in shares of TransMedics Group during the second quarter valued at about $1,140,000. Candriam S.C.A. raised its holdings in shares of TransMedics Group by 45.4% during the first quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock valued at $15,783,000 after purchasing an additional 49,580 shares during the period. Emerald Investment Advisers LLC bought a new position in shares of TransMedics Group during the 2nd quarter worth about $2,023,000. Finally, Wellington Management Group LLP boosted its position in shares of TransMedics Group by 6.1% during the 2nd quarter. Wellington Management Group LLP now owns 515,973 shares of the company’s stock worth $34,271,000 after purchasing an additional 29,500 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.
TransMedics Group Company Profile
TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.
TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.
Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.
Featured Articles
- Five stocks we like better than TransMedics Group
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
